Clinical Trial News Archive - March 2017
Get news by email or subscribe to our news feeds.
March 1, 2017
- SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients
- Myovant Sciences Initiates Phase 3 Clinical Trial of Relugolix in Men with Advanced Prostate Cancer
March 2, 2017
March 3, 2017
March 4, 2017
March 6, 2017
March 8, 2017
- Menlo Therapeutics Announces Successful Pruritus Reduction Results from Phase 2 Serlopitant Trial (TCP-102) in 127 Subjects With Prurigo Nodularis
- Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
March 9, 2017
- Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
- FDA Grants Orphan Drug Designation to Boehringer Ingelheim’s Investigational Anti-CD33 Monoclonal Antibody BI 836858 for Treatment of Myelodysplastic Syndromes
March 15, 2017
- BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax in Patients with Advanced Breast Cancer
- Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer
March 20, 2017
March 21, 2017
March 22, 2017
- Novartis Provides Update on Phase III study of RLX030 (serelaxin) in Patients with Acute Heart Failure
- New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor CSL830 in HAE Patients
- Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
March 27, 2017
- Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders
- Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
- Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
March 28, 2017
- Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
- Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis
- Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer
March 30, 2017
- Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
- Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma
- Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of Azedra
